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Metallothionein: Structure/Antigenicity and
DetectionlQuantittion in Normal
Physiological Fluids
by Justine S. Garvey*
Recent experiments in the application ofradioimmunoassay (RIA) in the detection and
quantitation of metallothionein (MT) in human sera and urines demonstrate that it is
possible to extend the lower limit ofpractical quantitation from the previous limit of50-
100pgto 1 pg. RIAofnormal seraindicatesthatthetypical range ofconcentrations ofMT
is from less than 0.01 ng/mL to about 1 ng/mL, and that concentrations above 2 ng/mL
should be considered abnormal. The typical range for normal urines is from less than 1
ng/mL to 10 ng/mL; concentrations above 10 ng/mL should be considered abnormal. A
complementary assay, the enzyme-linked immunosorbent assay (ELISA), is under devel-
opment. The ELISA is a competitive binding assay, detection and quantitation of MT
being either by colorimetric or fluorimetric methods. The present useful range for MT
quantitation in the ELISA is from about 50-50000 pg (fluorimetric) or 5005000 pg
(colorimetric).
Recentexperiments using the RIA have identified the principal antigenic determinants
of vertebrate MTs as involving the immediate amino terminal residues (-MDPNC-) and
the segment including residues 20-25 (-KCKECK-in human MT). Theoretical predictions
of secondary structure based on hydrophilicity and sequence analysis indicate that the
conformational proffle is dominated by tetrapeptide candidates for beta turns (reverse
turns) with2-3 hexapeptide sequences beingcandidates forhelical conformation and 4-5
short sequences (3-5 residues) being candidates for beta chain conformation. The helical
candidates are predicted to be unstable and the analysis favors reverse turns for both
determinants ofvertebrate MT and a sequestered location for thejoining region between
clusters A and B.
Introduction
Since the development of the double-antibody
radioimmunoassay (RIA) for metallothionein
(MT) in my laboratory (1-3) in 1977-1979, it has
been applied in numerous studies ofthat protein,
including application to the determination ofMT
content in human sera and urine prior to and
after exposure to cadmium (4-7), in the serum of
rats treated with cadmium and zinc (8), to the
identification ofcertainmetal-bindingproteins as
MTs (9,10) and to the determination ofthe degree
to which certain invertebrate metal-binding pro-
teins and candidate vertebrate MTs cross-react
with known vertebrate MTs. These studies stimu-
late interest in more firmly defining the typical
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range of concentrations of MT in physiological
fluids ofnormal human subjects and in similarly
defining more firmly the precise nature of the
reaction occurring in the RIA. Therefore, we have
made regular modifications and improvements to
the protocols to permit determinations of MT
content in body fluids at progressively decreasing
MT concentrations, and we have performed stud-
ies aimed at improving our knowledge of the
processes involved in the in vitro reactions be-
tween MT as antigen and the specific anti-MT
antibody. The former effort has gradually led to a
capability to extendthe lower limit ofdetection of
MT in body fluids from 1-2 ng/mL to 0.02 ng/mL.
As a complement to the RIA we have initiated
development of an enzyme-linked immunosor-
bent assay (ELISA). The effort to improve under-
standing of the details of the antigen-antibody
reaction has led to the identification ofthe princi-
pal antigenic determinants of vertebrate MTsJ. S. GARVEY
(11) and concomitantly to useful information con-
cerning the secondary, and perhaps some aspects
of the tertiary, structure of the protein. We dis-
cuss these recent improvements and applications
below.
Metallothionein in Normal Serum
and Urine
Detection/Quantitation by
Double-Antibody RIA
The protocols for the double-antibody RIA have
been previously described (1-3,12); we comment
briefly on them here. Conventionally, the antigen
(Ag), rat MT isolated from kidney or liver tissue,
is injected into rabbits to stimulate the produc-
tion of primary antibodies (Ab) which later are
used in the in vitro RIA to recognize and to bind
125I-labeled MT or unlabeled MT in competitive
binding assays. Known amounts of labeled and
unlabeled MT are used in conjunction with
known amounts ofprimary Ab and ofa secondary
Ab (goat anti-rabbit IgG) to produce a standard
curve that is then used to quantitate samples
containing unknown amounts of MT. The second
Ab is usedto precipitate Ag-Ab complexes, avoid-
ingthe complications which accompany the use of
chemical reagents rather than a second Ab for
this purpose. In our initial work we developed
linear regressions relating the fraction (Y) of
bound labeled MT to the log ofthe concentration
(X) of unlabeled MT. The practical limit was
about 2 ng/mL, this in part a consequence ofthe
sigmoid character ofthe response. Subsequently,
we developed inverse variance weighted logit-log
regressions (logit Y vs. log X) to express the
standard curve (13-18). Usual protocols lead to a
region of linear response ranging from approxi-
mately 10-90% bound labeled MT (and approxi-
mately 50-15000 pg unlabeled MT); the exten-
sions at high and low concentrations ofunlabeled
MT exhibit slopes about 1/4 that of the central
region, which typically has a slope near 1 (nega-
tive). Use of the extended region, particularly
that involving 0-50 pg unlabeled MT, is concomi-
tant with increasingly large uncertainties asso-
ciated with the increasing variance of measure-
ments as the fraction of bound labeled MT
approaches unity. However, with care in the ex-
perimental procedures one can develop standard
curves over this region permitting the quantita-
tion ofsamples with MT concentrations as low as
0.01 ng/mL. Typically, measurements at 2ng/mL
carry an SEM (standard error ofthe mean) of 5-
10% of the mean, and this increases gradually
over the next two decreasing orders ofmagnitude
in MT concentrations to about 100% ofthe mean
at 0.01 ng/mL; this sets the practical lower limit
ofquantitation at about 0.02 ng/mL.
Examples of some recent determinations ofMT
concentrations in normal human serum are
shown in Table 1. The results are from an experi-
mentpreliminary to the quantitation ofserafrom
humans sufferingdisorders associatedwithfaulty
metal metabolism and thus suspected of being
MT-related. As effort was therefore made to ex-
tend quantitation to include concentrations ofMT
at the absolute limit ofdetection. For the prelimi-
nary experiment, serum was collected from 17
carefully selected volunteers (Syracuse Univer-
sity students, young, healthy, nonsmokers), and
the MT content was determined in each such
sample. The distribution, with a median value at
approximately 0.1 ng/mL, may serve as a guide in
the continued development of kinetic theories of
metal and MT metabolism in the body (19,20).
As a test of reproducibility of results at the
limit ofdetection, separately prepared aliquots of
the samples with MT concentrations less than 0.1
ng/mL were then mixed (in varying amounts) for
the development of a standard curve by using 100
1L aliquots. The previously measured MT con-
tents ofthe original aliquots were used to calcit-
late the expected mean value for the mix of the
second set. The mean value calculated for the mix
was 0.043(0.017) ng/mL; the measured value for
the mix ofthe second set was 0.078(0.037) ng/mL.
The two mean values are not statistically distin-
guishable; note that two separate regressions are
involved here, the second slightly less accurate
than the first.
These results support the thesis that careful
handling of samples, especially the technique of
Table 1. Metallothionein (MT) concentrations in normal
human serum.a
MT range, ng/mLb Number
0.01 (0.01) - 0.10 (0.03) 8
0.10 (0.03) - 0.50 (0.12) 5
0.50 (0.12) - 1.00 (0.18) 4
aSamples from young, healthy, nonsmokers at Syracuse
University.
bStandard error of typical mean values at the indicated
concentrations in parentheses. Quantitation used two stan-
dard curves relating logit offraction bound labeled MT to log
(Q) ofconcentration (inpg) ofunlabeled MT. These intersected
at Q = 1.6317, corresponding to 42.83 pg unlabeled MT. The
two slopes (negative) in this system of units were 0.205 and
0.701, respectively. The correlation coefficient (negative) de-
creased from 0.987 (high concentration region) to 0.931 (low
concentration region).
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initially preparing separate aliquots of a given
sample prior to freezing and storage, minimizing
oxidizing atmospheres and handling times at ele-
vated temperatures, and use subsequently of a
given aliquot but once, permit experimental oper-
ations which lead to results in satisfactory agree-
ment with predictions or with previously deter-
minedresults, even when working at the absolute
limit ofpractical detection ofMT.
A similar set ofexperiments on MT content in
normal urines from the same group ofvolunteers
mentioned above led to a spectrum of concentra-
tions (group A, Table 2) which wehave found tobe
typical ofnormal urines. We include data (group
B, Table 2) from a determination ofMT content in
control urines submitted in conjunction with an
analysis of MT content in body fluids of patients
with neurological disorders and another set of
data (group C, Table 2) from a determination of
MT content in control urines submitted in con-
junction with an analysis of MT content in body
fluids of workers exposed to cadmium (5). The
three determinations were performed at various
times and under slightly different protocols; the
MT ranges listed and the associated standard
errors oftypical measurements are therefore not
identical. Additionally, the control urines were
measured concomitantly with samples expected
to have MT contents in excess of 10 ng/mL and
the standard curves developed for quantitation
had a practical lower limit ofdetection ofabout 1
ng/mL. The values of these three sets for those
samples listed in Table 2 with MT content less
than 10 ng/mL lead to a range of mean values,
each carrying an uncertainty ofabout 30%, from
2.8 to 5.1 ng/mL.
Table 2. Metallothionein (MT) concentrations in normal
human urine.a
Group A Group B Group C
MT range, MT range, MT range,
ng/mL Number ng/mL Number ng/mL Number
<2 2 <1.6 2 <1 6
2-5 3 1.6-2.6 9 1-2 5
5-10 4 2.6-5 8 2-5 3
> 10 lb 5-10 3 > 10 4c
aSamples in group A from young, healthy, nonsmokers at
Syracuse University. Samples in group B from controls sub-
mitted as part of an experiment on MT content in patients
with spina bifida (collaboration with A. Zimmerman, Univ. of
Connecticut). Samples in group C from controls submitted as
part of an experiment on workers exposed to cadmium (5).
Standarderrorsoftypical meansrange from 50% atthe lowest
reported concentrations to 15% at 10 ng/mL.
b22 ng/mL.
cOne value of130 ng/mL.
Summary Comments
The characteristic range of concentrations of
MT in normal sera is from undetectable to about
1 ng/mL; concentrations above 2 ng/mL are con-
sidered abnormal. The characteristic range for
normal urines is from less than 1 ng/mL to about
10 ng/mL; concentrations above 10 ng/mL are
considered abnormal. In normal subjects, the ra-
tio of urine MT/serum MT in a given case typi-
cally ranges from 10 to 50. In passing, we com-
ment that cytosols (kidney, liver) have MT
concentrations which are commonly orders of
magnitude greater than typical serum concentra-
tions. Measurements of samples of cytosols are
readily made in the central region ofthe standard
curve where standard errors ofthe mean ofmea-
surements are about 5% of the mean. In that
regard, if greater accuracy is desired, such is
attainable by relatively simple modifications of
the protocols for developing the standard curve.
Progress in Developing an ELISA
We have been working on the development of
an ELISA (21-23) or enzyme-linked immunosor-
bent assay as a complement to the RIA. The
protocol involves use ofan antigen (Ag) fixed to a
microtiter plate (fixed Ag), antigen subsequently
added in solution (free Ag) to compete with the
fixed Ag for a primary antibody (Abl), a second-
ary antibody (Ab2) conjugated to an enzyme, the
conjugate binding with the complex of fixed Ag-
Abl after disposing of the complex of free Ag-
Abl, and a substrate which binds to the enzyme
inthe conjugate. We have been usingthe enzyme,
alkaline phosphatase, conjugated to protein A.
The substrate maybe selected to permit detection
of the final complex by colorimetric or fluorime-
tric means. We have focused on the colorigenic
p-nitrophenyl phosphate and the fluorogenic
4-methylumbelliferyl phosphate in these two de-
tection methods.
At this writing the practical detection and
quantitation limits for MT are about 50-5000 pg
for fluorimetric methods and about 500-50000 pg
for colorimetric methods (J. Linton, unpublished
results). Errors have been about twice those typi-
cal ofthe RIA.
Antigenic Determinants and
Secondary Structure of MT
General
In the development of an RIA for the detection
and quantitation of a particular molecule (anti-
gen; Ag), there are two principal phases. The first
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is an in vivo phase in which the Ag stimulates an
immune response leading to the production of
other molecules (antibodies; Ab) specific for cer-
tain sites (determinants) on the Ag surface, these
sites commonly involving four to six residues and
to varying degrees influenced by the topography
ofthe surface near the site (24-26). This response
involves amino acid sequence, the presence of
charged residues, surface conformation, exposure
to solvent, and the character ofadjacent regions.
The specificity of the immune reaction is then
reflective ofthe characteristics ofprimary struc-
ture (sequence), secondary structure (helix, beta
chain, reverse turn, random coil, intra-chain in-
teractions) and tertiary structure (inter-chain in-
teractions). In the second, in vitro, phase, the
produced Ab molecule is used as a sensitive probe
ofsurface structure ofother molecules, both simi-
lar and dissimilar to the initial Ag ofthe in vivo
phase. The in vitro physical-chemical reaction is
again reflective ofthe same parameters of struc-
ture that characterized the in vivo reactions. In
conjunction with predictions ofrelative hydrophi-
licity (27-29) and of probable protein structure
from sequence analysis (30-34), one can interpret
the results of competitive binding RIAs to indi-
cate not only specific variations in sequence be-
tween Ag molecules and variations in surface
structure in and near determinants, but also to
indicate regions where the predictions of surface
structure (helices, beta chains, reverse turns)
based on sequence and hydrophilicity are either
confirmed or contradicted. Coupled to previously
available information from spectroscopic and
other experiments, the assay results can be used
to support or amend existing concepts of second-
ary structure, and to a certain extent tertiary
structure, and to suggest details of surface expo-
sure and core folding (35-37).
Our analysis ofthe structure ofMT is based on
the protocols developed by Chou and Fasman
(32,33)and influenced by the hydrophilicity scale
developed by Hopp and Woods (28), the latter in
turn based on the analysis ofrelative hydropho-
bicity ofamino acids by Nozaki and Tanford (27)
and subsequent modifications by Levitt (30,31).
The Chou/Fasman protocols are based on the
study of experimentally determined conforma-
tions in 29 proteins, primarily globular and
averaging about 150 residues each, including his-
tidine and the aromatics. These protocols replace
an earlier setbased on analysis of15 proteins; the
earlier set was the basis of a calculation (38)
which concluded that helices were forbidden in
human MT-2 and that beta chains were only
marginally possible. The improvedprotocolsmod-
ify significantly the earlier set and contain addi-
tional boundary conditions to permit more accu-
rate evaluation of the potential for a given
conformation to exist. In passing, we remark a
recent analysis (39) ofthe secondary structure of
human MT-2 using abbreviated Chou/Fasman
protocols (40) for determining candidate helices
and beta chains. However, the use ofthe numer-
ousboundary conditions inthe complete protocols
modifies the initial predictions regarding candi-
date conformations andadditionally we are inter-
ested in comparisons of potential antigenic sites
in the MTs of common use in the RIA (human,
rat, rabbit). An analysis ofsecondary structure in
the various isoforms ofthese MTs as derived from
the complete predictive theory is therefore requi-
site.
In applying these protocols to vertebrate MTs,
itshouldbenotedthat MT is smallerthanmostof
the proteins used to derive the protocols, has an
unusual amino acid composition, contains typi-
cally 16 ratherthan 20 amino acids, and is ellipti-
cal rather than globular (41-43). Further, it ex-
ists in the native state as two semi-independent
clusters (44-47) identified as cluster B (residues
1-29) and cluster A (residues 30-61). Secondary
structure will also be influenced by the fact that
the native proteinbinds 6-7 divalent metal atoms
at neutral pH (42,43) although recent potentio-
metric experiments indicate that the number of
cadmium atoms in a cadmium-MTboundstrongly
at pH 7 is only 5 (A. Avdeef, A. Zelazowski, and
J. S. Garvey, unpublished observations). The apo-
protein has been numerously reported as essen-
tially random coil (38,48,49); since the RIA dem-
onstrates cross-reactivity between the native
protein and the apoprotein (1-3), this suggests
that the apoprotein is conformable to the native
shape by the binding antibody, at least in respect
to antigenic determinants. There is no reported
firm experimental evidence for alpha helices or
beta chains in the native protein and a contribu-
tion of less than 5% to MT secondary structure
has been estimated from various spectroscopic
studies for these conformations (50).
Correlation ofPredicted Secondary
Structure ofMT with Experimentally
Derived Sites ofAntigenic
Determinants
The MTs analyzed by using the Chou/Fasman
protocols in association with the Hopp/Woods hy-
drophilicity profiles included the most commonly
reported isoforms of human, rabbit, rat and
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FIGURE 1. Amino acid sequences ofvertebrate metallothionein isoforms. Sequences shown are the most common variants ofeach
isoform. Substitutions with respect to human MT-2 are indicated. Sources: human MTs 1 and 2 (51-53); rabbit MT-B (54); rat
MTs 1 and 2 (55,56); equine Mts 1A and 1B (53,57,58). Mouse MTs I and II (59,60) are used to complete the sequences ofrat
MTs 1 and 2, respectively (in parentheses). The substitutions indicated for the various MT sequences with respect to that of
humanMT-2 arethe obligate ones only. Human MT-1 variants may involve the appearance ofP in position 9, V in position 10
or 12, the substitution ofAforT orvice versa in positions 9, 14 and 53, orE substituted for D in position 55. Rabbit MT-B may
substitute A for E in position 23.
equine MTs: human 1 and 2 (51-53), rabbit B
(54), rat 1 and 2 (55,56) and equine 1A and 1B
(53,57,58). Mouse MTs I and II (59,60) were used
to complete the incomplete sequences ofrat MTs.
Figure 1 exhibits the sequences of these various
MT isoforms. Note that because of numerous al-
lowed substitutions there exist variants of these
isoforms (43,61). The substitutions indicated for
the various MT sequences with respect to that of
human MT-2 are the obligate ones only (see Fig.
1). All the isoforms have 61 residues ofwhich 20
are cysteine (C), approximately 12 are charged
residues [aspartic acid (D), glutamic acid (E),
lysine (K) and arginine (R)], approximately 8 are
serine (S), another 10 are either alanine (A) or
threonine (T), approximately 5 are glycine (G),
and the remnant includes methionine (M), pro-
line (P), asparagine (N), glutamine (Q), leucine
(L), isoleucine (I) and valine (V). The aromatics
are absent and histidine (H) has been found only
in chicken MT (61). The amino terminus always
has an acetylated methionine followed by
-DPNCSC-through residue 7.
The antigenic determinants of vertebrate MT
have been identified (11) as localized in the seg-
ment -MDPNC- (residues 1-5) and the segment
of residues 20-25 (-KCKECK- in human MT).
Residues 30-61 (cluster A) exhibited trivial reac-
tivity. The experiment involved using anti-rat
MT antibody produced in rabbits. Rat MT cross-
reacts with human MT and equine MT with only
minor changes in affinity, implying that the same
or but slightly altered determinants are involved
inthe separate reactions. Inthisregard, although
the slopes ofstandard curves for rat, human, and
equine MTs are statistically indistinguishable,
those ofequine MTs are typically shifted slightly
inthe direction ofdecreased reactivity (2,12), and
this may reflect the modification of the determi-
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FIGURE 2. Hydrophilicity profile of human metallothionein
isoform 2. Hydrophilicity indices (kcal/mole free energy
change as solvent changes from water to an organic sol-
vent) are indicated for sequential hexapeptides according
to the protocol ofHopp and Woods (28). Values are plotted
in the center ofthe hexapeptide sequence. The Hopp/Woods
hydrophilicity scale derives from the amino acid solubility
studies of Nozaki and Tanford (27) as subsequently modi-
fiedby Levitt (30,31) and then again modified after empiri-
cal observations relating hydrophilicity and antigenicity.
The terminal regions are completed withvalues for penta-,
tetra-, tri- and di-peptides. The Hopp/Woods hydrophilicity
indices are as follows for the amino acids in Ml. 3(D, E, K,
R); 0.3(S); 0.2(N, Q); O(G, P); -0.4(T); -0.5(A); -1(C); -
1.3(M); -1.5(V);-1.8(I, L).
nant inthe regionofresidues 20-25 bythe substi-
tution ofR for K in position 25 and/or the substi-
tution ofQ for E in position 23.
Figure 2 exhibits the hydrophilicity profile of
human MT-2 according to the protocols of Hopp
and Woods (28); the profiles of the isoforms are
similar, the principal differences being in the
magnitudes attained at the relative maxima. The
protocols identify the hexapeptide (or its immedi-
ate neighborhood) with the maximum average
hydrophilicity index as an antigenic determi-
HUMAN MT-2
HUMAN MT-I
RABBIT WM-B
RAT MT-2
RAT MT- I
EOUINE MT-IA
EQUINE MT-IB
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nant; less certain identification is assigned hex-
apeptides of lesser hydrophilicity. For the verte-
brate MTs studied, relative maxima occur in the
region of residues 21-25, 29-33 and 52-58, with
lesser relative maxima in the region of residues
9-13 and 42-46, although in the case of equine
MT-1A and rat MT-1 the first mentioned region
remains hydrophobic and the second mentioned
region is minimally hydrophilic in all isoforms
studied. The extended regions of residues 5-17
and 34-52 are either hydrophobic or minimally
hydrophilic; the carboxyl terminal residues ex-
hibit significant hydrophobicity.
Figure 3 exhibits the reverse turn profile of
human MT-2 as derived from the Chou/Fasman
protocols, and also exhibits the segments which
qualify as potential candidates for helical or beta
chain conformation on the basis of their confor-
mational parameters (see Fig. 3); the latter two
classes particularly require additional analysis
(application ofboundary conditions) before a pre-
diction of their probable existence can be made.
The predictive protocols are based on the frequen-
cies ofappearance ofthe 20 common amino acids
in helices, beta chains, and reverse turns in the
4741 residues of 29 proteins. These frequencies
are enumerated for each position in such confor-
mations. A valuable boundary condition involves
the sextet ofresidues at the amino and carboxyl
terminals of helices and beta chains (i.e., the
three residues preceding the amino terminal and
the first three amino terminal residues, the last
three residues at the carboxyl terminal and the
first three residues following that terminal). The
continued product of the site frequencies of the
sextet at either terminal ofthe conformation rep-
resents a probability of formation which can be
compared to the average value for that sextet and
provides a guide in deciding on the probable oc-
currence of that conformation. A similar set ex-
ists for the tetrapeptides preceding and following
reverse turns (we comment that we have not
found this latter set of site frequencies to be as
useful as the sets for helices and beta chains).
Additional protocols involve the frequency of ap-
pearance of certain dipeptides and tripeptides in
helices, beta chains and reverse turns. Each
amino acid is then characterized with respect to
helix formation and beta chain formation as a
former (strong, moderate, weak), indifferent, or
breaker (moderate, strong). A given sequence,
influenced by residues adjacent to it, will have
potential for forming a particular conformation if
certain empirically derived conditions are met.
Helices involve six or more residues, beta chains
three or more residues, reverse turns four resi-
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FIGURE 3. Reverse turn (beta bend) profile of human metal-
lothionein isoform 2: ( _ ) helices; ( ) beta chains.
Probabilities Pt for sequential tetrapeptides to form a re-
verse turn according to the protocols ofChou and Fasman
(32,33) are plotted, with values indicated in the center of
the referenced tetrapeptide. The protocols are based on
analysis of 29 proteins (4741 residues) which leads to the
assignment ofa frequency ofappearance ofa given amino
acid in a specific position (1,2,3 or 4) in a reverse turn
(similar frequencies are developed for helices and beta
chains). The continued product ofthese site frequencies for
a specific set of four residues represents the probability
that the set will form a reverse turn. The average value is
0.55 x 10-4. Values about twice the average value indi-
cate a significant potential for such a conformation. Also
indicated are the segments which satisfy the primary
conditions of the protocols to qualify as candidates for
formation of helices or beta chains. The measure used is
the conformational parameter ofthe sequence; this is the
average value of the conformational parameters of the
member residues. In the analysis of the 29 proteins, each
amino acid has an observed frequency of appearance in a
particular conformation; this value divided by the fre-
quency of appearance ofall residues in that conformation
yields a number (conformational parameter; typically be-
tween 0 and 3) which is a member ofa normalized set of20
members. Ib be predicted as a stable conformation the
indicated helices and beta chains must additionally satisfy
certain boundary conditions and secondary conditions re-
garding the appearance of various dipeptides and tripep-
tides and the relative magnitude ofreverse turn potential
involving the same residues. These conditions compromise
the potential of both helices and at least three of the
candidate beta chains and make their stable existence
unlikely. The known structure of native MT (cluster for-
mation) compromises the potential of the other two beta
chain candidates.
dues. A given sequence or region may exhibit
potential forformingmore than one conformation
and variousboundary conditions are then applied
to resolve the ambiguity. The most favored resi-
dues for appearance in a helix (strong formers)
are E, M, A, L; moderately strong formers are K,
Q, I, V; strong breakers are P and G. The most
favored residues for forming a beta chain are V, I;
moderately strong formers are L, C, T, Q, M;
strong breakers are P, D, E. Residues in MT with
the largest values for frequency ofappearance in
thesequential fourpositions ofa reverse turn are:
(1) N, C, D, S; (2) P, then S, K, D, T, R; (3) N, G, D,
then S, C; (4) G, C, T, then S. For appearance in a
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reverse turn without regard to position the most
prominent residues are: N, G, P, D, S, then C, K.
The residue with the largest frequency ofappear-
ance in any position of a reverse turn is P in
position 2.
The reverse turn profile (Fig. 3) indicates that
almost half of the sequential tetrapeptides have
probabilities of formation which are in excess of
the average value by a factor oftwo or more and
as a class they dominate the complete conforma-
tional profile. The tetrapeptide common to all the
isoforms studied with the highest potential to
form a revese turn is -DPNC- (residues 2-5),
with a probability about 20 times the average
value of 0.55 x 10-4. This tetrapeptide is in a
hydrophilic region and would be predicted to be a
candidate for an antigenic determinant. The se-
quence -MDPNC- (residues 1-5) has been identi-
fied as a determinant and in this case the experi-
mental findings support the theoretical
prediction. We also mention that residues 37-40
in equine MT-1A (-CPGG-) and rabbit
MT-B(-CPSG-) have high reverse turn probabil-
ities (12.9 x 10-4 and 8.2 x 10-4); the region,
however, is hydrophobic. Other tetrapeptides in
human MT-2 of high turn potential include the
following in the principal hydrophilic regions:
residues 19-22 (-CKCK-), 55-58 (-DKCS-), 24-
27 (-CKCT-) and 53-56 (-ASDK-). Note that the
tetrapeptide -CKEC- (residues 21-24) qualifies
as a reverse turn with high potential (three times
the average value) on the basis of site frequen-
cies, but it is eliminated by the appearance ofthe
dipeptide, -KE-, which does not occur in reverse
turns. Numerous candidates appear in hydropho-
bic or minimally hydrophilic regions and would
not be predicted to appear in antigenic determi-
nants; such include the following of high turn
potential: residues 34-37 (-CSCC-), 57-60
(-CSCC-), 26-29 (-CTSC-), 15-18 (-CAGS-),
37-40 (-CPVG-), 11-14 (-DSCT-), 50-53
(-CKGA-), 45-48 (-AQGC-), 41-44 (-CAKC-),
17-20 (-GSCK-), 33-36 (-CCSC-), 31-34
(-KSCC-) and 38-41 (-PVGC-). Substitutions in
the other vertebrate isoforms modify the magni-
tude ofthe separate probabilities in the remarked
regions (vide infra).
The regions of highest potential for forming a
helix in human and rabbit MTs are those of
residues 20-25 (-KCKECK-) and ofresidues 42-
47 (-AKCAQG-). The first mentioned region re-
mains a candidate, even after the substitutions
indicated in Figure 1, in all the isoforms studied.
The second region is not a candidate in the other
MTs (rat and equine). Mouse MTs, used as a
pattern for rat MTs in cluster A, also have a helix
candidate in the region of residues 51-56
(-KGAADK- or -KQASDK-). Note that the re-
gion 20-25 is prominently hydrophilic, and the
region 42-47 is hydrophobic or minimally hydro-
philic; the region 51-56 is hydrophilic. The se-
quence -KCKECK- satisfies the primary condi-
tions for possible helix formation, but it has
certain unfavorable aspects. The dipeptide, -KE-
is unfavored for appearance in a helix and the
sequence fails to satisfy the boundary condition
mentioned earlier regarding the sextet of resi-
dues at either terminal of the helix. The contin-
ued product ofthe individual site frequencies for
the sextet of amino acids in the three positions
preceding the amino terminal of the candidate
helix andthe firstthreepositions atthatterminal
is less than 1/5 the average value for helix initia-
tion (0.67 x 10-9). Coupled to the disfavored
dipeptide, -KE-, this implies that the sequence
will not form a stable helix. The tetrapeptides -
CKCK- (residues 19-22) and -CKCT- (residues
24-27) have reverse turn probabilities three
times the average value. For human MTs and
rabbit MT-B we conclude that the antigenic de-
terminant in the region of residues 20-25 in-
volves one or both of the conformation(s) of the
mentioned reverse turns and one or more of the
charged residues in that sequence. The various
substitutions in the other isoforms do not change
the unfavorable character for helix formation of
the amino terminal sextet. In rat MT-1 the sub-
stitution of G for K in residue 20 leads to a
probability for helix initiation 1/3 the average
value, while having minimal observed effect on
the antigenicity of the region. The substitutions
ofQ for E in position 23 (as in equine MT-1B and
rat MT-2) or N for E in that position (as in rat
MT-1) orRforK inposition 25 (as in equine MTs)
slightly reduces but does not eliminate helix po-
tential. The various isoforms in this residue re-
gion also exhibit high reverse turn probabilities
forresidues 19-22 and 24-27 (-CGCK-,-CRCT-,
and -CRCA- have reverse turn probabilities two
to three times the average value). In sum, the
candidacy of residues 20-25 for helix formation
appears significantly compromised by the bound-
ary conditions and the higher potential of the
region to support reverse turns. In this regard,
reverse turns may terminate helices or beta
chains, one residue a member also ofthe joining
conformation. The Chou/Fasman protocols count
as reverse turns only those with no more than the
initial or final member of the turn common to
both conformations; they do not include those
types of reverse turns which may be considered
part of a helix. The competing potentials we em-
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phasize then are first those oftetrapeptides com-
mon to both conformations, then those with three
or two members in common. With the above con-
siderations in mind, and in view ofthe observed
cross-reactivity ofthese vertebrate isoforms, one
concludes that the antigenicity of the region is
controlled by the conformational contributions of
the mentioned reverse turns and the two charged
residues in positions 22 and 25 (K,K in human,
rabbit and rat MTs; presumably K,R in equine
MTs).
The sequence of residues 42-47 (-AKCAQG-)
in human MTs and rabbit MT-B is a helix candi-
date based on conformational parameter but the
sextet ofresidues at the amino terminal is unfa-
vorable for helix initiation (probability about 1/3
the average value). Residues 41-44 (-CAKC-)
and 45-48 (-AQGC-) have high turn probability
(about two and three times the average value).
The substitutions in rat MTs and equine MT-1A
in this region eliminate the sequence as a helix
candidate; in the latter case residues 44-47
(-CAGG-) have a very high turn probability
(about six times the average value), and in the
case ofthe rat MTs the substitution ofS for A in
residue 42 produces the tetrad -CSKC- which
has four times the average probability to form a
reverse turn. The hydrophobicity or minimal hy-
drophilicity ofthe region indicates that itwill not
support adeterminant, whetherthe conformation
is helix or turn. The unfavorable boundary condi-
tions for helix formation indicate that this region
does not support a stable helix; however, it may
be characterized by one or more reverse turns in
all the isoforms studied. In passing, we note that
the residues 48-50 (-CIC- or -CVC-) in all iso-
forms have high beta chain potential, and in
those isoforms with -QCx- in positions 46-47 the
pentapeptide -QGCIC- (or -QGCVC-) has high
betachainpotential andthis maycompromise the
formation ofthose reverse turn candidates which
include -QG-.
As noted, mouse MTs exhibit a potential helix
candidate in the theoretically hydrophilic region
ofresidues 51-56; in either case (-KGAADK- or
-KQASDK-) the amino terminal sextet is very
unfavorable to helix initiation (probabilities less
than 1/2o the average value). Extensions to in-
clude residues 43-57 fail to yield a satisfactory
conformational parameter (too few strong form-
ers). Additionally, there is competition in the
latter case with the beta chain candidates men-
tioned above (residues 48-50 or 46-50), which
have beta chain potentials exceeding the helix
potentials in that segment. Residues 50-53
(-CKGA-) and 55-58 (-DKCT-) in mouse MT-I
have reverse turn probabilities more than twice
the average value; and in mouse MT-II reverse
turn probability is high for residues 53-56, 54-
57, and 55-58 (-ASDK-, -SDKC-, and -DKCS-;
two, three and four times the average value,
respectively). Assumingthese residuescharacter-
izeratMTs, theregion ismostprobably one ofone
or more reverse turns; the failure ofthe region to
exhibit significant antigenicity presumably re-
flects suppression of the conformations by the
chelation process in native MT, even though the
sequence -DK- is favorable in reverse turns. The
hydrophobicity ofthe adjoining regions may also
act to suppress exposure and conformational po-
tentials. Note also that tryptic digestion cleaves
the -KO- bonds in cluster B but fails to do so in
cluster A (46), again implying a region less ex-
posed to solvent than theory would indicate.
Our discussion involving the potential confor-
mations in the isoforms ofMTs otherthan human
MT-2 has focused on the obligate sequences indi-
cated in Figure 1. The substitutions noted in the
legend of Figure 1 involving human MT-1 and
the residue region 9-14 tend to reduce the hy-
drophilicity index ofthe region and also the prob-
ability that the region will exhibit significant
antigenicity; the substitutions involving residues
53 and 55 have a slight influence on helix poten-
tial (residues 51-56) but the sextet ofresidues at
the amino terminal of that candidate remains
very unfavorable for helix initiation (less than
1/2o the average value for that sextet). The substi-
tution of A for E in position 23 in rabbit MT-B
slightly improves the helix potential of the se-
quence 20-25 while significantly improving the
reverse turn potential of all tetrads involving
positions 22 and 23; the hydrophilicity index of
the hexapeptide (residues 20-25) is reduced from
1.7 to 1.1, still a relative maxima and a candidate
antigenic site, its character dominated by reverse
turns andthetwo lysines. Inpassingwe comment
that mouse MT-I substitutes A for K (residue 20)
and D for E (residue 23) in the sequence 20-25.
The dipeptide -KD- is favorable to helix forma-
tion (and to reverse turn formation) as is the
sextet at the carboxyl terminal; however, the
sextet at the amino terminal has only half the
average probability for initiating a helix and re-
verse turn probability remains unchanged for
residues 24-27, only slightly reduced for residues
19-22 (still more than twice the average value)
and increases for residues 21-25. We conclude
that this isoform will exhibit a conformation and
antigenicity similar to that of the previously
mentioned isoforms. In this regard, certain
metal-binding proteins from mouse ascites cells
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(provided by David Petering, University of Wis-
consin) have been shown to cross-react in RIAs
with a rat liver (Cd, Zn)-MT and have been
tentatively identified as MTs (unpublished obser-
vations).
The failure ofthe theoretically hydrophilic re-
gion joining the two clusters, residues 27-33, to
exhibit antigenicity is perhaps a consequence of
the sequestering of the region between the two
clusters. The regionhasnohelixpotential buthas
aseries ofcandidate reverse turns withprobabili-
ties offormation between two and five times the
average value, and the dipeptide -KK- is favora-
ble for turn formation.
Antigenicity is not expected to involve the hy-
drophobic regions of the candidate beta chains.
We may note that ofthe five candidates in Figure
3, three have reverse turnpotentials which domi-
nate the beta chain potentials. These are residues
34-37, (-CSCC-) or the extension to 33-37
(-CCSCC-); residues 26-29 (-CTSC-); residues
57-60 (-CSCC-, although a possible exception is
the sequence in mouse MT-I, -CTCC-). Two seg-
ments, residues 13-15 (-CTO-) and48-50 (-CIC-
or -CVC- in some isoforms), compete favorably
with reverse turn and helix potentials, but they
exist in separate clusters in native MT. It is
concluded that coupling of any two segments of
the five is improbable and that beta structure in
native MT is at best unstable.
With respect to the previously remarked recent
analysis (39) ofthe secondary structure ofhuman
MT-2 using only the conformational parameters
of the abbreviated protocols (40) for predicting
candidates for helical orbeta chain conformation,
the predictions are similar, although not identi-
cal, to our own. That analysisfocuses, asdowe, on
the highpotential ofthe total sequence to support
reverse turns. In that regard, the recently modi-
fied sequence (53) at the carboxyl terminal (resi-
dues 57-60) changes -CCSC- to -CSCC- which
significantly enhances the reverse turn potential
ofthat tetrapeptide (see Fig. 3). The helix candi-
date listed inthe referenced analysis as involving
residues 41-46 is eliminated on applying the
boundary conditions regarding the sextet ofresi-
dues at the carboxyl terminal of that candidate.
As we have noted, even the permitted candidate
in that region (residues 42-47) has an unfavor-
able sextet ofresidues at the amino terminal for
initiating a helix. However, these differences in
analyses are minorwith respect to the correlation
ofstructure with antigenicity, residues 57-60 and
42-47 appearing in hydrophobic or minimally
hydrophilic regions and exhibiting insignificant
antigenicity.
Summary Comments
As noted earlier, the conclusions of others
(38,50) regardingthe existence ofeitherhelices or
beta chains in vertebrate MT isoforms have been
negative or at best unfavorable. The predictions
ofsecondary structure from our analysis are com-
patible with those conclusions, although they do
not absolutely rule out the possible fluctuating
existence of those conformations. The results of
the experiment onthe determinants ofvertebrate
MT, identifying -MDPNC- as a principal anti-
genic site, rather firmly support the theoretical
prediction of a prominent exposed reverse turn
(-DPNC-) atthe amino terminal. Andthe results
suggest that the determinant in the region of
residues 20-25 (-KCKECK- in human MT) owes
its character to reverse turns (residues 19-22
and/or 24-27) involving exposed and charged res-
idues. The results also suggest that the joining
region of clusters A and B may be sequestered
between the two clusters and that the theoretical
hydrophilicity and possible antigenicity of the
region is consequently suppressed. Similarly, the
results may be interpreted to suggest that the
theoretical hydrophilicity and potential antigen-
icity of segments near the carboxyl terminal of
cluster A may be suppressed inthe native protein
as a consequence of the chelation process, with
potential antigenicity also compromised by small
structural fluctuations reflecting competing con-
formational potentials.
Note added in press: A recent analysis of the
sequence ofratMTsbyD. R. Winge (unpublished)
indicates the following substitutions in the se-
quences listed in the text. Rat MT-1: S for T in
position 17; S for A in position 54. Rat MT-2: A
for S in position 42; S for A in position 45, E for Q
in position 52. In all cases these variations, al-
though mildly influencing conformational poten-
tials, leave unchanged the conclusions ofthe text
regarding probable conformations in the affected
regions. In MT-1 regional turn potentials in-
crease slightly andthe beta chainpotential in the
region of residue 17 is slightly decreased. In
MT-2 turn potentials in the affected regions vary
slightly, the beta chain potential in the region of
residue 45 remains high, and the sequence 51-56
remains unfavorable for helix initiation with res-
idues 53-57 still predicted to be a turn. The
presence of E in position 52 does increase the
hydrophilicity index of those hexapeptides of
which it is a member, the maximum value (1.5)
increasing to 2.0. Again, the failure ofthe region
to exhibit significant antigenicity supports the
conclusion of the text that the adjoining hydro-
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phobic regions act to suppress in the native pro-
tein the exposure to solvent ofthe region ofresi-
dues 51-56.
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